Please use this link to access this publication. Summary Cannabis potency, defined as the concentration of Δ9-tetrahydrocannabinol (THC), has increased internationally, which could increase the risk of adverse health outcomes…
Condition: Psychosis
A Systematic Review of the Effectiveness of Medical Cannabis for Psychiatric, Movement and Neurodegenerative Disorders
Abstract The discovery of endocannabinoid’s role within the central nervous system and its potential therapeutic benefits have brought forth rising interest in the use of cannabis for medical purposes. The…
Does dopamine mediate the psychosis-inducing effects of cannabis? A review and integration of findings across disciplines
Please use this link to access this publication. Abstract General population epidemiological studies have consistently found that cannabis use increases the risk of developing psychotic disorders in a dose-dependent manner….
Potential antipsychotic properties of central cannabinoid (CB1) receptor antagonists
Please use this link to access this publication. Abstract Δ9-Tetrahydrocannabinol (Δ9-THC), the principal psychoactive constituent of the Cannabis sativa plant, and other agonists at the central cannabinoid (CB1) receptor may induce characteristic…
Individual and combined effects of acute delta-9-tetrahydrocannabinol and cannabidiol on psychotomimetic symptoms and memory function
Abstract The main active ingredient in cannabis, delta-9-tetrahydrocannabinol (THC), can acutely induce psychotic symptoms and impair episodic and working memory. Another major constituent, cannabidiol (CBD), may attenuate these effects. This…
Cannabidiol (CBD) as a novel treatment in the early phases of psychosis
Abstract The pharmacological interventions available for individuals in the early stages of psychosis are extremely limited. For those at clinical high risk for psychosis, there is no licensed treatment available….
Genetic Predisposition vs Individual-Specific Processes in the Association Between Psychotic-like Experiences and Cannabis Use
Please use this link to access this publication. Key Points Question To what extent is the association between cannabis use and psychotic-like experiences attributable to predispositional (ie, shared genetic) or to…
A single dose of cannabidiol modulates medial temporal and striatal function during fear processing in people at clinical high risk for psychosis
Abstract Emotional dysregulation and anxiety are common in people at clinical high risk for psychosis (CHR) and are associated with altered neural responses to emotional stimuli in the striatum and…
Effects of short-term cannabidiol treatment on response to social stress in subjects at clinical high risk of developing psychosis
Abstract Rationale Stress is a risk factor for psychosis and treatments which mitigate its harmful effects are needed. Cannabidiol (CBD) has antipsychotic and anxiolytic effects. Objectives We investigated whether CBD…